Navigation Links
Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease
Date:10/19/2010

SAN DIEGO, Oct. 19 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).

The launch of Phase 2 follows a fully enrolled Phase 1 portion that demonstrated early safety using an enhanced CERE-120 dosing regimen targeting the substantia nigra and putamen, two brain areas especially affected by Parkinson's disease. This study is enrolling at 11 major medical centers throughout the United States and includes investigators Drs. Mark Stacy and Dennis Turner at Duke University School of Medicine, Drs. Catherine Cho and Ron Alterman at Mount Sinai Medical Center, New York, and Drs. Stewart Factor and Nicholas Boulis at Emory University Hospital, who were all involved in treating the patients in the Phase 1 portion of this study.

Additional clinical sites include Columbia University Medical Center, NYC, NY; Beth Israel Medical Center, NYC, NY; University of Pennsylvania Hospital, Philadelphia, PA; University of Alabama, Birmingham, AL; Rush University Medical Center, Chicago, IL; Baylor College of Medicine, Houston, TX; University of California, San Francisco, CA and Stanford University School of Medicine, Palo Alto, CA.

Details on the clinical study can be found at www.ceregene.com or www.clinicaltrials.gov/ct2/show/NCT00985517.

This Phase 2b clinical study is partially funded by a $2.5M LEAPS (Linked Efforts to Accelerate Parkinson's Solutions) award from The Michael J. Fox Foundation for Parkinson's Re
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Ceregene Presents Long-term Follow-up From Phase 1 Trial of CERE-120 in Parkinsons Disease
2. Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
3. Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
4. Echo Therapeutics Initiates Needle-Free Biosensor Program for Continuous Lactate Monitoring
5. LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine
6. ISTA Pharmaceuticals Initiates Phase 3 Clinical Program for REMURA™ in Dry Eye Disease
7. N30 Pharma Initiates Phase 1 Trials of Novel Reductase Inhibitor
8. Vanda Pharmaceuticals Initiates Phase III Clinical Study Aimed at Resetting the Body Clock
9. Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
10. Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
11. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Unichem Pharmaceuticals ( ... one lot of Hydrochlorothiazide tablets 25 mg 1000-count bottle ... as a precautionary measure due to the identification of ... product. The risk associated with mistakenly ... is the increased probability of experiencing Clopidogrel,s side effects ...
(Date:7/30/2015)... 30, 2015 Tianyin Pharmaceutical Inc. (NYSE Amex: ... specializes in the patented biopharmaceutical, modernized traditional Chinese medicine ... updates regarding the notice it received on May 21, ... that the Company was below certain of the Exchange,s ... and 1101 of the NYSE MKT Company Guide, due ...
(Date:7/30/2015)... July 30, 2015 ... report with market overview, trends, DRO analysis, ... analysis, recent developments, competitive scenario and top ... Insight: Biosensors Market Development and Demand Forecast ... http://photos.prnewswire.com/prnh/20150727/756778 ) Explore more about ...
Breaking Medicine Technology:Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5
... Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced ... (MAA) with the European Medicines Agency (EMA) for lorcaserin, ... weight loss and maintenance of weight loss, in patients ... overweight (BMI >27) and have at least one weight-related ...
... Corporation (NASDAQ: IRIX ) today announced that ... conferences this month. The Company presents today ... Conference where President and CEO Dominik Beck will host ... the day.  The Company is also ...
Cached Medicine Technology:Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control 2Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control 3Arena Pharmaceuticals Files European Marketing Authorization Application for Lorcaserin for Weight Control 4
(Date:7/31/2015)... ... ... According to WFLA on July 16th, Sarasota has seen at least ... deaths have held steady over the last “couple of months” according to WFLA. Law ... spurred by the crackdown of prescription painkillers. Many users who were addicted to prescription ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... Practice, and Hospital Medicine Practice, is pleased to announce that it has partnered ... application format available on iPhones, iPads, and Android smartphones and tablets. , ...
(Date:7/31/2015)... ... 2015 , ... An article entitled " Dentists Doing Dermatology? ... unfortunate experience having cosmetic skin procedures done by a family doctor not board-certified ... bruising, and pain. This woman’s experience is only one in a series of ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... of a wide variety of nutritional and wellness products, announced the addition of ... specializes in massage therapy, active isolated stretching and the prevention and rehabilitation of ...
(Date:7/31/2015)... ... 31, 2015 , ... People love to feel like they ... price is an important factor to clients when choosing to purchase a policy. ... Preferred Producer Multi-Life Discount program, where advisers pass savings onto their clients. , ...
Breaking Medicine News(10 mins):Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 2Health News:Dermatologists Discuss Rise in Unqualified Practitioners of Cosmetic Dermatology 3Health News:NPI Welcomes Vincent Aquilino to Board of Directors 2Health News:Secura Consultants Gives Advisers Competitive New Edge with Multi-Life Discount Program 2
... fear and anxiety are involved, and the amygdalathe brain,s almond-shaped ... But the amygdala doesn,t do its job alone. Scientists at ... the fear map to part of the brain known as ... MD, PhD, found that mice lacking a critical growth factor ...
... scientists at Carnegie Mellon University,s Language Technologies Institute (LTI) ... on Haitian Creole so that translation tools desperately needed ... earthquake-ravaged island can be rapidly developed. Since Carnegie Mellon ... a team at Microsoft Research has used it to ...
... ... ... HealthWorks Medical Group, a leading nationwide operator of on-the-job-injury health and urgent care centers, today ... by getting workers vaccinated against H1N1., , , , ,“U.S. HealthWorks wants to send our ...
... mice ,rejuvenated, when treated with blood factors from younger mice, ... have found a way to make old stem cells in ... could lead to ways to slow the aging process. , ... putting them in old mice made old stem cells take ...
... stem cell therapy, but much research remains to be ... at Stanford University have succeeded in creating brain nerve ... tails of adult mice. , The new approach could ... how cells choose and maintain their specialized roles in ...
... ... Vice Chairwoman, Stephanie DeKemper takes ownership. , ... Indianapolis, IN (PRWEB) Jan. 27, 2010 -- SynCare, LLC ( www.syncarellc.com ) announced ... of Directors Vice Chairwoman Stephanie DeKemper. , , , , ,An aggressive and well-respected consumer ...
Cached Medicine News:Health News:Brain scientists extend map of fear memory formation 2Health News:Carnegie Mellon releases data on Haitian Creole to hasten development of translation tools 2Health News:Twitter Contest: Free, Onsite H1N1 Vaccination Day for Winning Businesses 2Health News:Aging of Blood Stem Cells May Be Reversible 2Health News:Scientists Turn Mouse Skin Cells Into Nerve Cells 2Health News:Scientists Turn Mouse Skin Cells Into Nerve Cells 3Health News:SynCare, LLC Completes Sale of Assets to Stephanie DeKemper 2Health News:SynCare, LLC Completes Sale of Assets to Stephanie DeKemper 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: